Clinical Trials

5 results for Kidney/Renal Cancer


PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

  • Condition: Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in Lymph Node, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Malignant Neoplasm in the Viscera, Sarcomatoid Renal Cell Carcinoma
  • Intervention: Drug: Cabozantinib, Biological: Ipilimumab, Biological: Nivolumab, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
  • Study ID: NCT03793166
View Trial

A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)

  • Condition: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
  • Intervention: Drug: Selenomethionine (SLM), Drug: Axitinib, Drug: Selenomethionine (SLM), Drug: Axitinib
  • Study ID: NCT02535533
View Trial

A Phase I/IB Study of Avelumab in Combination With Gemcitabine for Advanced Renal Cell Carcinoma With Sarcomatoid Differentiation

  • Condition: Metastatic sRCC
  • Intervention: Drug: Avelumab, Drug: Gemcitabine
  • Study ID: NCT03483883
View Trial

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Axitinib, Drug: Avelumab
  • Study ID: NCT03341845
View Trial

A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)

  • Condition: Carcinoma, Renal Cell
  • Intervention: Drug: Spartalizumab, Drug: Canakinumab
  • Study ID: NCT04028245
View Trial